We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure [email protected]
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter explores new technologies for overcoming the problem of deteriorating oocyte-quality with age. It includes brief discussions of the following: mitochondrial replacement therapy, cytoplasmic transfer, autologous germline mitochondrial energy transfer (AUGMENT), maternal spindle transfer (MTS), in vitro activation of dormant follicles, autologous activated platelet-rich plasma injections (PRP), in vitro gametogenesis, induced pluripotent stem cells (iPSCs), aneuploidy correction through gene-editing and artificial ovaries. Clinicians should exercise extreme caution in managing patient expectations regarding these novel technologies. While clinical application of stem cell technology for maternal age-related infertility does seem likely at some point in the future, the timeline remains uncertain.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.